Supplementary Figure 1. Changes in TSC2 expression and mTORC1 activation in nipple angiofibromas. Tumor fibroblast-like cells from nipple angiofibromas (T) and control fibroblasts from normal-appearing skin (C) were grown in Dulbecco's Modified Eagle Medium supplemented with 10% fetal bovine serum and then switched to serum -free DMEM for 24 hrs. Cells were lysed in protein extraction buffer and equal amounts of protein extracts resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto PVDF membranes (Invitrogen). The blots were probed with rabbit anti-tuberin/TSC2 (D93F12), anti-phospho-S6 ribosomal protein (Ser 235/236), and anti-S6 ribosomal protein (Cell Signaling, Danvers, MA).
a. Cultured fibroblasts from a nipple angiofibroma from P27 has a nonsense TSC2 c.4375C>T p.(Arg1459*) at an allele frequency of 99%, consistent with both a germline mutation and second hit genomic loss of the wild-type allele (loss of heterozygosity) as seen in the Integrative Genome Viewer (IGV) screenshot. b. P28 has a TSC2 c.4868_4875delCCCTGATG mutation at an allelic frequency of 54% as seen in IGV. cd. Patients P36 and P37, who are related, have the same germline splice site mutation TSC2 c.2098-1G>A at an allelic frequency of 50% as seen in IGV (c) and validated by Sanger sequencing (d). ef. P36 angiofibroma had a second hit missense mutation TSC2 c.4858C>T p. (His1620Tyr) at an allelic frequency of 5%. IGV screenshot (e) and SNaPshot single nucleotide sequencing validation (f) are shown. The mutation was not identified in the SNP variant server ExAC and has been previously reported in TSC patients (http://www.lovd.nl/, accessed 14 October 2015). It is likely to be pathogenic as predicted by Polyphen and due to its presence in the TSC2 GTP-ase Activating Protein (GAP) domain, a mutation hotspot region where nearby variants were found to be pathogenic (Hoogeveen-Westerveld et al., 2013) . gh. P37 angiofibroma (P37T1) had a second hit splice site mutation TSC2 c. 138+1G>A at an allelic frequency of 5%. IGV screenshot (g) and SNaPshot single nucleotide sequencing validation (h) are shown. ij. P37 angiofibroma (P37T2) had a second hit nonsense TSC2 c.3574C>T p. (Gln1192*) mutation at an allelic frequency of 3%. IGV screenshot (i) and SNaPshot single nucleotide sequencing validation (j) are shown. kl. P47 angiofibroma had a nonsense TSC2 c.3999C>A p.(Tyr1333*) mutation at an allelic frequency of 50% as seen in IGV (k) and validated by Sanger sequencing (l).
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